#184 – AMA #29: GLP-1 Agonists – The Future of Treating Obesity?
“Getting deeper into how this drug works has certainly made me appreciate its power.” —Peter Attia
#171 – Steve Austad, Ph.D.: The landscape of longevity science: making sense of caloric restriction, biomarkers of aging, and possible geroprotective molecules
“I never thought [extending the human lifespan] was going to happen because we got better at treating cancer or we got better at preventing heart disease. I always thought it was going to happen because we would develop something … that would fundamentally change the rate of aging. And we haven’t developed that yet. We’ve got a lot of clues and I think we’re getting closer and closer and closer.” —Steve Austad
#148 – Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program
“I don’t really care what causes aging. What I care about is: What is the process that can postpone all the different aspects of aging?” — Rich Miller
#140 – Gerald Shulman, M.D., Ph.D.: A masterclass on insulin resistance—molecular mechanisms and clinical implications
“If we can understand insulin resistance, then that’s going to be the best way to fix diabetes, heart disease,. . .fatty liver disease, and slow down cancers.” — Gerald Shulman
Replacing sugar with allulose
Allulose is on the top of my sweetener preference list for both objective and subjective reasons.
A few things worth sharing: 10-04-2020
Longevity in mice; The wonders of F1.
#120 – AMA with Dom D’Agostino, Ph.D., Part II of II: Ketosis for cancer and chronic disease, hyperbaric oxygen therapy, and the effect of ketosis on female health
“The function of the mitochondria and mitochondrial health are the ultimate mitigator of neurodegenerative diseases…just by reducing the potential for reactive oxygen species related damage.” — Dom D’Agostino